{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T01:40:34Z","timestamp":1778118034015,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ZIA ES101074"],"award-info":[{"award-number":["ZIA ES101074"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ZIA ES101081"],"award-info":[{"award-number":["ZIA ES101081"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR041215-02"],"award-info":[{"award-number":["AR041215-02"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Myositis Association and Cure JM Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To identify and validate biomarkers in JDM patients using a multiplexing tandem mass tag urine proteome profiling approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>First morning void urine samples were collected from JDM patients (n\u2009=\u200920) and healthy control subjects (n\u2009=\u200921) and processed for analysis using a standardized liquid chromatography-tandem mass spectrometry approach. Biomarkers with significantly altered levels were correlated with clinical measures of myositis disease activity and damage. A subset of candidate biomarkers was validated using commercially available ELISA kits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 2348 proteins were detected in the samples, with 275 proteins quantified across all samples. Among the differentially altered proteins, cathepsin D and galectin-3 binding protein were significantly increased in the urine of JDM patients (adjusted P\u2009&amp;lt;\u20090.05), supporting previous findings in myositis patients. These two candidate biomarkers were confirmed with ELISAs. Cathepsin D positively correlated with Myositis Damage Index (r\u2009=\u20090.57, P\u2009&amp;lt;\u20090.05) and negatively correlated with the Childhood Myositis Assessment Scale (r\u2009=\u2009\u22120.54, P\u2009&amp;lt;\u20090.05). We also identified novel JDM candidate biomarkers involved with key features of myositis, including extracellular matrix remodelling proteins.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study confirmed the presence of several proteins in the urine of JDM patients that were previously found to be elevated in the blood of myositis patients and identified novel candidate biomarkers that require validation. These results support the use of urine as a source for biomarker development in JDM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead033","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T20:50:59Z","timestamp":1674161459000},"page":"3161-3168","source":"Crossref","is-referenced-by-count":6,"title":["Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-5653","authenticated-orcid":false,"given":"Melissa","family":"Morales","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Binghamton University\u2014State University of New York , Binghamton, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tchilabalo D","family":"Alayi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Binghamton University\u2014State University of New York , Binghamton, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shefa M","family":"Tawalbeh","sequence":"additional","affiliation":[{"name":"Department of Biomedical Systems and Informatics Engineering, Yarmouk University , Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes V","family":"Sydenstricker","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Spathis","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Binghamton University\u2014State University of New York , Binghamton, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-6533","authenticated-orcid":false,"given":"Hanna","family":"Kim","sequence":"additional","affiliation":[{"name":"Juvenile Myositis Pathogenesis and Therapeutics Unit, National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health (NIH) , Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Binghamton University\u2014State University of New York , Binghamton, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yetrib","family":"Hathout","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Binghamton University\u2014State University of New York , Binghamton, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-2458","authenticated-orcid":false,"given":"Lisa G","family":"Rider","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH) , Bethesda, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"2023090115150334700_kead033-B1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2023090115150334700_kead033-B2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.55563\/clinexprheumatol\/56ilob","article-title":"Juvenile dermatomyositis. Where are we now?","volume":"40","author":"McCann","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2023090115150334700_kead033-B3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023090115150334700_kead033-B4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"2023090115150334700_kead033-B5","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1093\/rheumatology\/keaa371","article-title":"Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis","volume":"60","author":"Kishi","year":"2021","journal-title":"Rheumatology"},{"key":"2023090115150334700_kead033-B6","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/art.21378","article-title":"The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids","volume":"52","author":"Ramanan","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2023090115150334700_kead033-B7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2023090115150334700_kead033-B8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine"},{"key":"2023090115150334700_kead033-B9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpeds.2017.12.053","article-title":"Advances in juvenile dermatomyositis: myositis specific antibodies aid in understanding disease heterogeneity","volume":"195","author":"Pachman","year":"2018","journal-title":"J Pediatr"},{"key":"2023090115150334700_kead033-B10","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology"},{"key":"2023090115150334700_kead033-B11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023090115150334700_kead033-B12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3389\/fimmu.2019.00638","article-title":"A path to prediction of outcomes in juvenile idiopathic inflammatory myopathy","volume":"10","author":"Reed","year":"2019","journal-title":"Front Immunol"},{"key":"2023090115150334700_kead033-B13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40674-020-00168-5","article-title":"Juvenile dermatomyositis: new clues to diagnosis and therapy","volume":"7","author":"Pachman","year":"2021","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2023090115150334700_kead033-B14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/art.21331","article-title":"Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies","volume":"53","author":"Chung","year":"2005","journal-title":"Arthritis Care Res"},{"key":"2023090115150334700_kead033-B15","first-page":"1681","article-title":"Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies","volume":"48","author":"Rider","year":"2002","journal-title":"Clin Chem"},{"key":"2023090115150334700_kead033-B16","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1073\/pnas.1507719112","article-title":"Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy","volume":"112","author":"Hathout","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023090115150334700_kead033-B17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3899\/jrheum.161128","article-title":"Urine biomarkers to predict response to lupus nephritis therapy in children and young adults","volume":"44","author":"Brunner","year":"2017","journal-title":"J Rheumatol"},{"key":"2023090115150334700_kead033-B18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2023090115150334700_kead033-B19","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","article-title":"Measures for adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2023090115150334700_kead033-B20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2023090115150334700_kead033-B21","doi-asserted-by":"crossref","first-page":"26504","DOI":"10.1021\/acsomega.0c03206","article-title":"Tandem mass tag-based serum proteome profiling for biomarker discovery in young duchenne muscular dystrophy boys","volume":"5","author":"Alayi","year":"2020","journal-title":"ACS Omega"},{"key":"2023090115150334700_kead033-B22","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2353\/ajpath.2010.100050","article-title":"Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers","volume":"177","author":"Nogalska","year":"2010","journal-title":"Am J Pathol"},{"key":"2023090115150334700_kead033-B23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/s10165-011-0568-7","article-title":"Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity","volume":"22","author":"Yanaba","year":"2012","journal-title":"Mod Rheumatol"},{"key":"2023090115150334700_kead033-B24","doi-asserted-by":"crossref","first-page":"154966","DOI":"10.1016\/j.cyto.2019.154966","article-title":"The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis","volume":"127","author":"De Paepe","year":"2020","journal-title":"Cytokine"},{"key":"2023090115150334700_kead033-B25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41927-020-00150-7","article-title":"Serum protein biomarkers for juvenile dermatomyositis: a pilot study","volume":"4","author":"Tawalbeh","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2023090115150334700_kead033-B26","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/rheumatology\/keaa721","article-title":"The diagnostic value of GDF-15 for myocardial involvement in idiopathic inflammatory myopathy","volume":"60","author":"Qiu","year":"2021","journal-title":"Rheumatology"},{"key":"2023090115150334700_kead033-B27","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2023090115150334700_kead033-B28","volume-title":"R: a language and environment for statistical computing","author":"Core Team R","year":"2018"},{"key":"2023090115150334700_kead033-B29","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2023090115150334700_kead033-B30","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1016\/j.csbj.2021.05.015","article-title":"The DisGeNET cytoscape app: exploring and visualizing disease genomics data","volume":"19","author":"Pi\u00f1ero","year":"2021","journal-title":"Comput Struct Biotechnol J"},{"key":"2023090115150334700_kead033-B31","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/gb-2006-7-9-r80","article-title":"The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins","volume":"7","author":"Adachi","year":"2006","journal-title":"Genome Biol"},{"key":"2023090115150334700_kead033-B32","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1021\/pr2003038","article-title":"A comprehensive map of the human urinary proteome","volume":"10","author":"Marimuthu","year":"2011","journal-title":"J Proteome Res"},{"key":"2023090115150334700_kead033-B33","doi-asserted-by":"crossref","first-page":"e1008002","DOI":"10.1371\/journal.ppat.1008002","article-title":"Inducible LGALS3BP\/90K activates antiviral innate immune responses by targeting TRAF6 and TRAF3 complex","volume":"15","author":"Xu","year":"2019","journal-title":"PLoS Pathog"},{"key":"2023090115150334700_kead033-B34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"2023090115150334700_kead033-B35","doi-asserted-by":"crossref","first-page":"e12955","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko","year":"2021","journal-title":"Brain Pathol"},{"key":"2023090115150334700_kead033-B36","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"2023090115150334700_kead033-B37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"2023090115150334700_kead033-B38","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023090115150334700_kead033-B39","doi-asserted-by":"crossref","first-page":"e000026","DOI":"10.1136\/lupus-2014-000026","article-title":"Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus","volume":"1","author":"Nielsen","year":"2014","journal-title":"Lupus Sci Med"},{"key":"2023090115150334700_kead033-B40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0961203317736144","article-title":"The involvement of galectin-3 in skin injury in systemic lupus erythematosus patients","volume":"27","author":"Shi","year":"2018","journal-title":"Lupus"},{"key":"2023090115150334700_kead033-B41","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0006-291X(02)00637-X","article-title":"Identification of autoantibodies associated with systemic lupus erythematosus","volume":"295","author":"Lim","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"2023090115150334700_kead033-B42","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/rheumatology\/keaa305","article-title":"Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity","volume":"60","author":"Watanabe","year":"2021","journal-title":"Rheumatology"},{"key":"2023090115150334700_kead033-B43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.biopha.2018.05.148","article-title":"Cathepsins: proteases that are vital for survival but can also be fatal","volume":"105","author":"Patel","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"2023090115150334700_kead033-B44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2119\/molmed.2010.00016","article-title":"A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis","volume":"16","author":"Nader","year":"2010","journal-title":"Mol Med"},{"key":"2023090115150334700_kead033-B45","doi-asserted-by":"crossref","first-page":"20101","DOI":"10.1038\/srep20101","article-title":"Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease","volume":"6","author":"Fox","year":"2016","journal-title":"Sci Rep"},{"key":"2023090115150334700_kead033-B46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12969-017-0182-0","article-title":"Cardiac findings in children with juvenile dermatomyositis at disease presentation","volume":"15","author":"Cantez","year":"2017","journal-title":"Pediatr Rheumatol Online J"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead033\/49101703\/kead033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3161\/51329051\/kead033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3161\/51329051\/kead033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T15:38:42Z","timestamp":1693582722000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/9\/3161\/6994178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":46,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,1,20]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead033","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,1,20]]}}}